Tayal V, Mandal A, Haque M I, Mishra A, Kalra BS, Roy V. Anticonvulsant potential of rosuvastatin in combination with carbamazepine and valproate in animal models of epilepsy. World J Methodol 2025; 15(2): 99580 [DOI: 10.5662/wjm.v15.i2.99580]
Corresponding Author of This Article
Vandana Tayal, MBBS, MD, Professor, Department of Pharmacology, Maulana Azad Medical College, Bahadur Shah Zafar Marg, New Delhi 110002, India. vandana_tayal@yahoo.com
Research Domain of This Article
Medicine, Research & Experimental
Article-Type of This Article
Basic Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Methodol. Jun 20, 2025; 15(2): 99580 Published online Jun 20, 2025. doi: 10.5662/wjm.v15.i2.99580
Anticonvulsant potential of rosuvastatin in combination with carbamazepine and valproate in animal models of epilepsy
Vandana Tayal, Akash Mandal, Ijasul Haque M, Akhilesh Mishra, Bhupinder S Kalra, Vandana Roy
Vandana Tayal, Akash Mandal, Bhupinder S Kalra, Vandana Roy, Department of Pharmacology, Maulana Azad Medical College, New Delhi 110002, India
Ijasul Haque M, Department of Pharmacology, MES Medical College, Perintalmanna 679338, Kerala, India
Akhilesh Mishra, Department of Central Animal Facility, Maulana Azad Medical College, New Delhi 110002, India
Author contributions: Tayal V, Mandal A and Haque MI interpreted the data and wrote the manuscript; Tayal V, Mandal A, and Mishra A designed, performed the experiments, acquired and analyzed the data; Kalra BS and Roy V were involved in the conceptualization of the study, literature review, and revising the manuscript for intellectual content; all authors read and approved the final version of the manuscript.
Institutional review board statement: This study was reviewed and approved by Maulana Azad Medical College, Institutional Review Board, No. 82/10/2020/152.
Institutional animal care and use committee statement: All animal handling and experiments were conducted according to the internationally accepted principles for the care and use of laboratory animals (after approval of Institutional Animal Ethics Committee, Maulana Azad Medical College, New Delhi, India, No. MAMC/IAEC/2021/02).
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Vandana Tayal, MBBS, MD, Professor, Department of Pharmacology, Maulana Azad Medical College, Bahadur Shah Zafar Marg, New Delhi 110002, India. vandana_tayal@yahoo.com
Received: July 25, 2024 Revised: October 11, 2024 Accepted: November 4, 2024 Published online: June 20, 2025 Processing time: 125 Days and 1.9 Hours
Abstract
BACKGROUND
Epilepsy impacts millions of people, with many not responding to existing treatments. Some evidence links neuroinflammatory processes to epilepsy. Statins exhibit anti-inflammatory and neuroprotective properties, potentially offering antiepileptic effects.
AIM
To evaluate the anticonvulsant effects of rosuvastatin in animal models of epilepsy.
METHODS
Ninety-six albino mice were divided into 16 groups. In the maximal electroshock seizure (MES) model, eight groups received intraperitoneal vehicle, carbamazepine, rosuvastatin, or a combination. Outcomes measured included seizure protection [tonic hind limb extension (THLE)], duration of THLE, seizure duration, and mortality. In the pentylenetetrazol (PTZ) model, eight groups were pretreated with vehicle, valproate, rosuvastatin, or a combination, with outcomes measured as seizure latency, seizure duration, and mortality.
RESULTS
In the MES model, rosuvastatin exhibited protection against THLE in a small percentage of mice. Rosuvastatin shortens the duration of THLE in a dose-dependent manner. However, none of these were statistically significant compared to the control group. The combination of rosuvastatin 10 mg/kg with carbamazepine 4 mg/kg resulted in a significant reduction in seizure duration compared to the control group, better than carbamazepine alone at 4 mg/kg and 6 mg/kg. In the PTZ model, rosuvastatin alone showed no significant effects on latency, duration of seizure, or mortality. However, rosuvastatin 10 mg/kg combined with valproate 100 mg/kg significantly delayed the onset of seizures, seizure duration and mortality percentage, better than valproate alone at 100 mg/kg.
CONCLUSION
Rosuvastatin enhanced the anticonvulsant effects of carbamazepine and valproate. Further studies are required to explore the antiepileptic potential of rosuvastatin at various doses, durations, dosage forms, routes and models.
Core Tip: Many patients do not benefit from the available antiepileptics. Statins are known for their pleiotropic effects, which include neuroprotective properties. We investigated whether rosuvastatin, a potent statin, has anticonvulsant properties on its own or if it potentiates the effects of standard anticonvulsants. The study used maximal electroshock and pentylenetetrazol seizure models in albino mouse We observed that rosuvastatin potentiated some of the anticonvulsant effects of the standard antiepileptics carbamazepine and valproate.
